Tryton bifurcation lesion stent
This article was originally published in The Gray Sheet
Executive Summary
Newton, Mass.-based Tryton Medical enrolls one-third of its 30-patient, three-site European feasibility study for the Side-Branch stent, the firm announces Oct. 10. The balloon-expandable stent is used in conjunction with standard coronary stents to treat bifurcation lesions that split into vessels' side branches. The firm hopes to begin a pivotal trial for a drug-eluting version of the product - likely partnering to use a sirolimus derivative - within a year and a half, according to Tryton Chief Technical Officer Richard Davis. The product could reach the U.S. market as early as 2009, he said. According to Tryton, 540,000 procedures for bifurcation lesions are performed each year, representing 20% of all coronary lesions treated. The firm hopes Side-Branch will fill a gap in treatment options to become a new standard of care for these challenging cases...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.